|
The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Prior to 1993, when the IPI was developed, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of predicting survival outcomes, and so other factors were studied. A retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin-based chemotherapy regimen such as CHOP between 1982 and 1987.〔A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94〕 Several patient characteristics were analyzed to determine whether they were associated with differences in survival, and the factors that emerged as significant were, in addition to the Ann Arbor stage: age, elevated serum lactate dehydrogenase (LDH), performance status, and number of extranodal sites of disease. == International Prognostic Index == One point is assigned for each of the following risk factors: * Age greater than 60 years * Stage III or IV disease * Elevated serum LDH * ECOG/Zubrod performance status of 2, 3, or 4 * More than 1 extranodal site The sum of the points allotted correlates with the following risk groups: * Low risk (0-1 points) - 5-year survival of 73% * Low-intermediate risk (2 points) - 5-year survival of 51% * High-intermediate risk (3 points) - 5-year survival of 43% * High risk (4-5 points) - 5-year survival of 26% 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「International Prognostic Index」の詳細全文を読む スポンサード リンク
|